Royalty Pharma (RPRX) Q2 Receipts Up 20%

Royalty Pharma Plc (NASDAQ:RPRX), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its closest revenue proxy—rose 11% to $672 million but landed just under the $672.99 million analyst estimate (GAAP). Portfolio Receipts, a non-GAAP metric which tracks cash inflows from all royalties and milestones, increased 20% to $727 million. The quarter highlighted strong cash generation, a major partnership with Revolution Medicines, and a continued shift toward a more diversified portfolio. Despite a marginal revenue miss (GAAP) and some product headwinds, the quarter reinforced the company’s robust growth and ongoing evolution. Management responded by raising full-year 2025 Portfolio Receipts guidance to $3,050 million to $3,150 million. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Royalty Pharma acquires rights to future royalty streams on approved and late-stage biopharma products. By doing so, it earns a share of sales from medicines across various fields, while the original drug developer handles research, production, and marketing.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool